Original Article

Right ventricular dysfunction in patients with COVID-19 pneumonitis whose lungs are mechanically ventilated: a multicentre prospective cohort study

P. J. McCall, J. M. Willder, B. L. Stanley, C-M. Messow, J. Allan, L. Gemmell, A. Puxty, D. Strachan, C. Berry, B.G. Shelley on behalf of the COVID-RV co-investigators*

1 Honorary Clinical Senior Lecturer, 11 Honorary Clinical Associate Professor, the Anaesthesia, Critical Care and Perioperative Medicine Research Group, University of Glasgow, Glasgow, UK
2 Consultant, Department of Anaesthesia, Golden Jubilee National Hospital, Clydebank, UK
3 Specialty Trainee, West of Scotland School of Anaesthesia, NHS Education for Scotland, Glasgow, UK
4 Junior Biostatistician, 5 Independent Biostatistician, Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK
6 Consultant, Department of Intensive Care Medicine, University Hospital Crosshouse, Kilmarnock, UK.
7 Consultant, Department of Intensive Care Medicine, Royal Alexandra Hospital, Paisley, UK
8 Consultant, Department of Intensive Care Medicine, Glasgow Royal Infirmary, Glasgow, UK
9 Consultant, Department of Intensive Care Medicine, University Hospital Wishaw, Wishaw, UK
10 Professor, Department of Cardiology and Imaging, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK

Summary
Cardiovascular complications due to COVID-19, such as right ventricular dysfunction, are common. The combination of acute respiratory distress syndrome, invasive mechanical ventilation, thromboembolic disease and direct myocardial injury creates conditions where right ventricular dysfunction is likely to occur. We undertook a prospective, multicentre cohort study in 10 Scottish intensive care units of patients with COVID-19 pneumonitis whose lungs were mechanically ventilated. Right ventricular dysfunction was defined as the presence of severe right ventricular dilation and interventricular septal flattening. To explore the role of myocardial injury, high-sensitivity troponin and N-terminal pro B-type natriuretic peptide plasma levels were measured in all patients. We recruited 121 patients and 118 (98%) underwent imaging. It was possible to determine the primary outcome in 112 (91%). Severe right ventricular dilation was present in 31 (28%), with interventricular septal flattening present in nine (8%). Right ventricular dysfunction (the combination of these two parameters) was present in seven (6%, 95%CI 3–13%). Thirty-day mortality was 86% in those with right ventricular dysfunction as compared with 45% in those without (p = 0.051). Patients with right ventricular dysfunction were more likely to have: pulmonary thromboembolism (p < 0.001); higher plateau airway pressure (p = 0.048); lower dynamic compliance (p = 0.031); higher plasma N-terminal pro B-type natriuretic peptide levels (p = 0.006); and raised plasma troponin levels (p = 0.048). Our results demonstrate a prevalence of right ventricular dysfunction of 6%, which was associated with increased mortality (86%). Associations were also observed between right ventricular dysfunction and aetiological domains of: acute respiratory distress syndrome; ventilation; thromboembolic disease; and direct myocardial injury, implying a complex multifactorial pathophysiology.

Correspondence to: P. J. McCall
Email: philip.mccall@glasgow.ac.uk

© 2022 The Authors. Anaesthesia published by John Wiley & Sons Ltd on behalf of Association of Anaesthetists. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Accepted: 6 April 2022  
Keywords: ARDS; COVID-19; echocardiography; right ventricle  
*see Appendix 1.  
Twitter: @philipmccall; @SivellScotland; @DrJSAllan; @lisaarkley3; @apuxty; @domstrachan; @ColinBerryMD; @GJanaesresearch

Introduction
COVID-19 can result in acute hypoxemic respiratory failure, which in severe cases may require admission to ICU and invasive mechanical ventilation. Haemodynamic instability and cardiac complications are prevalent, with right ventricular dysfunction a common finding [1–7]. The combination of acute respiratory distress syndrome (ARDS), invasive mechanical ventilation, thromboembolic disease and the potential for direct myocardial injury create an environment where right ventricular dysfunction is likely to occur [8]. In reports before the COVID-19 pandemic, right ventricular dysfunction was thought to occur in up to 55% of patients with ARDS and had been found to be independently associated with mortality, with more severe ARDS associated with an increased frequency of right ventricular dysfunction [9,10].

Previous echocardiographic studies in patients with COVID-19 have demonstrated right ventricular dysfunction and highlighted its association with adverse clinical outcomes [2–4,11]. However, much of the research into right ventricular dysfunction in COVID-19 has been retrospective and performed in undifferentiated cohorts of patients whose lungs are or are not mechanically ventilated [4–6]. There have been no robust, prospective, haemodynamic evaluations of patients with COVID-19 focusing specifically on the ICU population [3]. This study was designed as a pragmatic, critical care clinician-led, prospective echocardiography study to elucidate the prevalence of right ventricular dysfunction in patients with COVID-19 whose lungs are ventilated, its association with mortality and plausible causative mechanisms.

Methods
The study protocol and methods have been reported previously [12]. We conducted a prospective, observational cohort study involving 10 ICUs in NHS Scotland. Ethics approval was obtained, as was informed consent from a legal representative for all patients. Patients were eligible for inclusion if they were aged > 16 y with confirmed SARS-CoV-2 infection, with severe acute respiratory failure requiring tracheal intubation and positive pressure ventilation in ICU. Study imaging was performed > 48 h after tracheal intubation and before day 14 of ICU admission. We did not study patients with any of the following criteria: pregnancy; ongoing participation in investigational research that may undermine the scientific basis of the study; previous participation in the study; requirement for extracorporeal membrane oxygenation; and end-of-life care, where the patient was not expected to survive > 24 h.

Study data were collected and managed using REDCap (Vanderbilt University, Nashville, TN, USA) electronic data-capture tools hosted by the University of Glasgow. Baseline characteristics, chronic comorbidities, clinical trajectory before ICU admission, severity of illness, acute comorbidities and follow-up data were all collected prospectively. Clinical data relating to potential mechanisms of right ventricular dysfunction were also collected, specifically regarding the four domains of: ARDS; disordered coagulation; myocardial injury; and mechanical ventilation.

Participants underwent a single transthoracic echocardiogram to determine the presence or absence of right ventricular dysfunction between day 2 and day 14 following tracheal intubation, with all other echocardiographic imaging performed at the discretion of treating clinical teams. To reflect the clinical practice of bedside echocardiography in ICU, and for the purposes of determining the primary outcome of the study, imaging was in keeping with the protocol for a focused intensive care echocardiography (FICE) scan [13]. The presence or absence of severe right ventricular dilation along with the presence or absence of interventricular septal flattening (in systole, diastole or both) was established. Severe right ventricular dilation was determined from the apical four-chamber view at end-diastole and was present when right:left ventricular area ratio > 1. High-sensitivity troponin (I or T depending on assay used clinically at each site) and N-terminal pro B-type natriuretic peptide (NT-proBNP) were measured in all patients on the day of echocardiography. Samples were processed alongside routine clinical samples in each host site and therefore subject to routine laboratory quality assurance processes. Raised values were defined for NT-proBNP.
Total number of patients requiring mechanical ventilation admitted to participating ICUs during study period (n=507)

Total recruited to COVID-RV (n=121)

Excluded (n = 3)
- Extubated prior to echocardiography (n = 1)
- Technical factors meaning echocardiography not possible (n = 2)

Total included for analysis (n = 118)

Excluded (n = 6)
- Unable to determine primary outcome

Total included for primary outcome analysis. (n = 112)

Figure 1 Patient recruitment and flow diagram.

(> 300 ng.ml⁻¹) and troponin (TnT ≥ 15 ng.l⁻¹ or TnI ≥ 34 ng.l⁻¹ for males and ≥ 16 ng.l⁻¹ for females).

The primary outcome was the prevalence of right ventricular dysfunction and its association with 30-day mortality [12]. Right ventricular dysfunction was defined as the presence of severe right ventricular dilation and interventricular septal flattening. Exploratory outcomes sought to determine associations between right ventricular dysfunction and proposed aetiological factors. In addition, associations between cardiac biomarker levels and 30-day mortality were assessed. Sample size selection was, by necessity, a pragmatic balance of maximising available information vs. the delivery of the study. Given the number of patients admitted to participating ICUs in Scotland during the first wave of the pandemic (March–June 2020), we believed it was realistic to recruit 120–150 patients across participating sites. Power calculations were performed for estimated right ventricular dysfunction prevalence rates of 25% and 50%, with an overall mortality rate of 50% (see online Supporting Information Table S1). These analyses suggest that a study of 120 patients would have 80% power to detect an associated OR for mortality of 2.83–3.43 (with an estimated prevalence of right ventricular dysfunction of 50% and 25% respectively).

The proportion of patients with COVID-19 whose lungs were ventilated with right ventricular dysfunction was determined, with a 95%CI utilising the Clopper–Pearson method. We then sought to analyse the association of right ventricular dysfunction with 30-day mortality using logistic regression analysis predicting 30-day mortality from presence or absence of right ventricular dysfunction, adjusting for baseline characteristics (age; sex; ethnicity), phase of disease (time from tracheal intubation to echocardiography) and baseline severity of illness (APACHE-2 score). Firth’s bias-reduced logistic regression was used where ordinary logistic regression failed due to small numbers [14]. Ordinal and categorical data are presented as number (proportion). Between-group differences were assessed using Fisher’s exact test for categorical variables and Student’s t-test or Wilcoxon Mann–Whitney test for continuous variables. Statistical analyses were performed using R version 4.0.0 (R Foundation for Statistical Computing, Vienna, Austria).

Results

Between 2 September 2020 and 22 March 2021, we recruited 121 patients (Fig. 1, Table 1). Following recruitment, three patients were excluded from further participation: one due to
Table 1  Characteristics of patients with COVID-19 at the time of ICU admission. Values are mean (SD), number (proportion) or median (IQR [range]).

|                                | All patients n = 112 | No or less than severe right ventricular dysfunction n = 105 | Severe right ventricular dilation and septal flattening n = 7 | p value |
|--------------------------------|----------------------|-------------------------------------------------------------|---------------------------------------------------------------|---------|
| Age; y                         | 59 (11.3)            | 59 (11.6)                                                   | 61 (4.4)                                                     | 0.318   |
| Sex; male                      | 74 (66%)             | 69 (66%)                                                   | 5 (71%)                                                      | > 0.99  |
| BMI; kg/m²                     | 33 (7.1)             | 33 (7.2)                                                   | 32 (4.6)                                                     | 0.467   |
| Missing                        | 2                    | 2                                                          | -                                                            |         |
| Ethnicity                      |                      |                                                             |                                                              |         |
| White                          | 100 (89%)            | 93 (89%)                                                   | 7 (100%)                                                     | > 0.99  |
| Non-white                      | 12 (11%)             | 1 (1%)                                                     | -                                                            |         |
| Time from symptom onset to tracheal intubation; days |  | 11 (7–16 [0–46]) | 11 (7–14 [0–46]) | 18 (13–25 [7–33]) | 0.035   |
| Clinical Fraility Score        | 2 (2–3 [1–5])        | 2 (2–3 [1–5])                                              | 2 (1.5–2.5 [1–3])                                            | 0.281   |
| Missing                        | 1                    | 1                                                          | -                                                            |         |
| APACHE-2 score                 | 17 (5.8)             | 17 (5.8)                                                   | 18 (6.1)                                                     | 0.687   |
| Missing                        | 5                    | 5                                                          | -                                                            |         |
| Coronavirus clinical characterisation consortium mortality score | 10 (2.7)            | 10 (2.8)                                                   | 11 (2.3)                                                     | 0.712   |
| Missing                        | 10                   | 10                                                         | -                                                            |         |
| Smoking                        |                      |                                                             |                                                              |         |
| Non-smoker                     | 63 (56%)             | 61 (58%)                                                   | 2 (29%)                                                      | 0.228   |
| Ex-smoker > 1 year             | 40 (36%)             | 36 (34%)                                                   | 4 (57%)                                                      |         |
| Current or within 1 year       | 9 (8%)               | 8 (8%)                                                     | 1 (14%)                                                      |         |
| Alcohol                        |                      |                                                             |                                                              |         |
| None                           | 34 (31%)             | 33 (32%)                                                   | 1 (14%)                                                      | 0.478   |
| Minimal                        | 57 (52%)             | 51 (50%)                                                   | 6 (86%)                                                      |         |
| Moderate                       | 8 (7%)               | 8 (8%)                                                     | -                                                            |         |
| Excess                         | 11 (10%)             | 11 (11%)                                                   | -                                                            |         |
| Hypertension                   | 38 (34%)             | 36 (34%)                                                   | 2 (29%)                                                      | > 0.99  |
| Coronary artery disease        | 11 (10%)             | 11 (11%)                                                   | -                                                            | > 0.99  |
| Diabetes mellitus              | 33 (30%)             | 31 (30%)                                                   | 2 (29%)                                                      | > 0.99  |
| Asthma                         | 16 (14%)             | 15 (14%)                                                   | 1 (14%)                                                      | > 0.99  |
| Chronic obstructive pulmonary disease | 10 (9%)           | 10 (10%)                                                   | -                                                            | > 0.99  |
| Treatments before tracheal intubation |                    |                                                             |                                                              |         |
| Intravenous corticosteroids    | 74 (66%)             | 70 (67%)                                                   | 4 (57%)                                                      | 0.687   |
| Non-invasive positive pressure ventilation | 76 (68%) | 70 (67%) | 6 (86%) | 0.426   |
| High-flow nasal oxygen         | 65 (58%)             | 59 (56%)                                                   | 6 (86%)                                                      | 0.235   |
| Awake self-proning             | 57 (51%)             | 51 (49%)                                                   | 6 (86%)                                                      | 0.114   |
| New arrhythmias                | 17 (15%)             | 14 (13%)                                                   | 3 (43%)                                                      | 0.07    |

©2022 The Authors. Anaesthesia published by John Wiley & Sons Ltd on behalf of Association of Anaesthetists.
tracheal extubation before echocardiography and two due to technical factors preventing imaging. In the whole cohort, 30-day mortality was 47%. Out of 118 patients where echocardiography was performed, it was possible to determine the primary outcome in 112 (95%). Echocardiography was performed by British Society of Echocardiography-accredited echocardiographers in 55 (47%), FICE-accredited critical care clinicians with ‘mentor’ status in 37 (31%), FICE-accredited clinicians in eight (7%) and clinicians without any formal accreditation in 18 (15%). Imaging was performed a median (IQR [range]) of 5 (4–8 [2–14]) days following tracheal intubation.

Thirty-one (28%) patients had evidence of severe right ventricular dilation (right:left ventricular area ratio > 1:1) and nine (8%) had evidence of interventricular septal flattening. Right ventricular dysfunction (the combination of these two parameters) was present in seven patients (6%, 95%CI 3–13%) (Fig. 2). Subjective right ventricular dysfunction (determined qualitatively by the clinician performing echocardiography) was present in 86% with right ventricular dysfunction, in contrast to 10% of those without (p < 0.001). Subjective left ventricular dysfunction was present in 29% with right ventricular dysfunction, in contrast to 10% of those without (p = 0.168) (Table 2). There was no difference in time from tracheal intubation to imaging in patients with or without right ventricular dysfunction (p = 0.942). However, median (IQR [range]) time from symptom onset to echocardiography was longer in patients with right ventricular dysfunction as compared with without (23 [20–30 [15–37]]) vs. 17 (13–21 [3–51]) days, p = 0.017, respectively (Table 2).

Patients with right ventricular dysfunction had a higher plasma creatinine at the time of imaging and were more likely to be undergoing renal replacement therapy (Table 3). Heart rate was higher in patients with right ventricular dysfunction and acid–base status was also more disordered, with lower plasma pH, lower base excess and lower bicarbonate (Table 3). Six (86%) patients with right ventricular dysfunction were deceased by the time of 30-day follow-up compared with 47 (45%) without (p = 0.051) (Table 4). When testing for independent association, Firth’s bias-reduced regression analyses controlling for baseline characteristics, phase of disease and baseline severity of illness showed the presence of right ventricular dysfunction was associated with an increased 30-day mortality (OR 5.12, 95%CI 0.99–51.38; p = 0.051) (Table 5).

Radiologically confirmed or clinically suspected pulmonary thromboembolic disease was present in 57% of patients with right ventricular dysfunction compared with 5% in those without (p < 0.001). In keeping with this, treatment with anticoagulation was more common in those with right ventricular dysfunction (Table 3). There was no difference in: platelet count; prothrombin time; activated partial thromboplastin time; and D-dimer levels between the two groups (Table 3). Where it could be measured, plateau airway pressure was higher and pulmonary compliance was lower in patients with right ventricular dysfunction (Table 3). There was no difference in: peak airway pressure; positive end expiratory pressure; driving pressure; or indexed tidal volume between the groups (Table 3). There was no difference in PaO₂/FIO₂ ratio, requirement for prone positioning in the previous 24 h or Murray lung injury score [15] between the groups (Table 3).

There was no difference in the proportion of patients with normal or abnormal NT-proBNP levels, between those

| Table 1 (continued) | All patients n = 112 | No or less than severe right ventricular dysfunction n = 105 | Severe right ventricular dilation and septal flattening n = 7 | p value |
|---------------------|---------------------|-------------------------------------------------|-------------------------------------------------|---------|
| Pulmonary thromboembolic disease | | | | |
| Radiologically confirmed | 4 (4%) | 1 (1%) | 3 (43%) | < 0.001 |
| Clinically suspected | 5 (5%) | 4 (4%) | 1 (14%) | - |
| No | 101 (90%) | 98 (93%) | 3 (43%) | - |
| Unknown | 2 (2%) | 2 (2%) | - | - |
| Acute coronary syndrome | 5 (5%) | 5 (5%) | - | > 0.99 |
| Requirement for renal replacement therapy | 18 (16%) | 16 (15%) | 2 (29%) | 0.313 |
with and without right ventricular dysfunction (Table 3). However, median NT-proBNP values were higher in those patients with right ventricular dysfunction (Fig. 3). Conversely, there was no difference in troponin levels (I or T) between the groups (Table 3). However, raised troponin values were more frequent in patients with right ventricular dysfunction. Given the low frequency of the combination of severe right ventricular dilation and septal flattening (the primary outcome), on an exploratory basis, an alternative outcome describing the presence of severe right ventricular dilation and/or interventricular flattening was examined. This occurred in 33 (30%) patients (Fig. 2). Subjective right ventricular dysfunction was present in 44% of patients with this definition of right ventricular dysfunction, compared with 3% without ($p < 0.001$). Like the primary outcome definition of right ventricular dysfunction, patients with the alternative outcome were more likely to have confirmed or suspected thromboembolic disease, lower base excess and higher plateau airway pressure (see online Supporting Information Tables S2–S4). However, in contrast to the primary outcome, patients with the alternative outcome had: a higher sequential organ failure assessment score on the day of echocardiography; higher activated partial thromboplastin time; increased requirement for vasopressors; and lower PaO$_2$/FiO$_2$ ratio (see online Supporting Information Table S4). There was also no association with the phase of disease regarding time from symptom onset to tracheal intubation (see online Supporting Information Table S2). Mortality in this group was 52%, in contrast to 46% in those with no evidence of right ventricular dysfunction ($p = 0.679$, online Supporting Information Table S5). Regression analyses controlling for
baseline characteristics, phase of disease and baseline severity of illness demonstrated the presence of this definition of right ventricular dysfunction was not independently associated with 30-day mortality (OR 1.35 (95%CI 0.54–3.46); p = 0.523) (see online Supporting Information Table S6).

**Discussion**

This is one of the first studies to prospectively explore the prevalence of right ventricular dysfunction in patients with COVID-19 whose lungs were mechanically ventilated and its association with mortality. The prevalence of right ventricular dysfunction was 6% and this was associated with a mortality of 86%, in contrast to 45% in those without right ventricular dysfunction. A universal definition of right ventricular dysfunction has not yet been well established. It has been suggested the term refers to structural changes (abnormal imaging and/or biomarkers) but with maintained cardiac output, a clinical setting which may progress to fulminant right ventricular failure. Right ventricular failure is characterised by insufficient delivery of blood from the right ventricle along with elevated systemic venous pressures [16]. As right ventricular failure is a challenging clinical diagnosis to make, we referred to echocardiographic changes as right ventricular dysfunction. There is, however, a high likelihood that included patients with a diagnosis of right ventricular dysfunction would also have fitted the clinical criteria for right ventricular failure, where there was associated tachycardia, evidence of systemic hypoperfusion (disordered acid–base status), renal dysfunction and increased mortality.

Echocardiographic assessment of right ventricular function is challenging due to its complex geometry, retrosternal position and marked load dependence. As a result, there is no gold standard quantitative measurement of right ventricular function. International guidelines advocate assessment should incorporate a combination of both qualitative and quantitative parameters [17]. These quantitative methods, however, have been observed to vary markedly in their diagnostic performance [18]. More importantly, for our study, they are not assessed as part of a focused, bed-side FICE scan. We deliberately selected a pragmatic definition of right ventricular dysfunction to empower bed-side critical care clinicians to make the diagnosis [19]. Identification of right ventricular dysfunction could inform patient prognosis, alert to the potential for associated pathologies, such as thromboembolic disease, and influence treatment strategies such as optimisation of mechanical ventilation and introduction of inotropic support or pulmonary vasodilators. Furthermore, should any interventional study of right ventricular therapies be proposed in this patient group, it is imperative that any inclusion criteria allow the treating bed-side clinician to make the diagnosis.

The echocardiographic combination of right ventricular dilation and septal flattening is commonly referred to as acute cor pulmonale and is thought to demonstrate a severe form of right ventricular dysfunction.
Table 3  Characteristics of patients with COVID-19 whose lungs were mechanically ventilated on the day of echocardiography. Values are number (proportion), mean (SD) or median (IQR [range]).

|                              | All n = 112 | No or less than severe right ventricular dysfunction n = 105 | Severe right ventricular dilation and septal flattening n = 7 | p value |
|------------------------------|-------------|-------------------------------------------------------------|-------------------------------------------------------------|---------|
| Mechanical ventilation in the prone position | 79 (71%)    | 72 (69%)                                                   | 7 (100%)                                                   | 0.24    |
| Sequential organ failure assessment score | 7.9 (3)     | 7.8 (2.9)                                                    | 9.3 (4.2)                                                  | 0.408   |
| Requirement for RRT on day of echocardiogram | 15 (13%)    | 12 (11%)                                                    | 3 (43%)                                                  | 0.049   |
| Arterial [H+]; nmol.l⁻¹ | 39 (36–46 [28–68]) | 39 (35–45 [28–63])                                        | 53 (53–61 [49–68])                                         | 0.001   |
| Missing | 15          | 2                                                         |                                                          |         |
| Arterial PaO₂; kPa | 9.3 (1.2) | 9.3 (1.3)                                                   | 8.8 (1.0)                                                  | 0.219   |
| PaCO₂; kPa | 7 (6–8 [4–13]) | 7 (6–8 [4–1])                                              | 8 (6–9 [5–13])                                            | 0.39    |
| Missing | 3           | -                                                        |                                                          |         |
| Arterial base excess; mmol.l⁻¹ | 5.9 (6.5) | 6.4 (6.4)                                                  | -1.2 (3.2)                                                  | < 0.001 |
| Missing | 2           | -                                                        |                                                          |         |
| Arterial bicarbonate; mmol.l⁻¹ | 32 (6.6) | 32 (6.6)                                                  | 26 (2.7)                                                  | < 0.001 |
| Missing | 3           | -                                                        |                                                          |         |
| Plasma haemoglobin; g.dl⁻¹ | 11 (1.8) | 11 (1.8)                                                  | 10 (1.2)                                                  | 0.073   |
| Plasma neutrophils; ×10⁹ l⁻¹ | 11 (9–15 [3–43]) | 11 (9–15 [3–43])                                        | 10 (8–13 [6–19])                                          | 0.512   |
| Plasma lymphocytes; ×10⁹ l⁻¹ | 1 (1–1 [0–5]) | 1 (1–1 [0–5])                                            | 1 (1–2 [0–2])                                             | 0.341   |
| Plasma platelets; ×10⁹ l⁻¹ | 280 (110) | 282 (107)                                                  | 243 (148)                                                  | 0.518   |
| Plasma C-reactive protein; mg.l⁻¹ | 62 (12–158 [1–665]) | 60 (10–156 [1–665])                                      | 71 (29–186 [11–279])                                      | 0.528   |
| Plasma D-dimer; mg.l⁻¹ | 1264 (601–2605 [1–30,667]) | 1315 (573–2652 [1–30,667])                                | 1156 (1105–1485 [890–2144])                              | 0.961   |
| Missing | 31          | 2                                                        |                                                          |         |
| Prothrombin time; s | 12 (11–13 [10–26]) | 12 (11–13 [10–26])                                       | 13 (11–15 [11–17])                                         | 0.434   |
| Activated partial thromboplastin time; s | 27 (25–31 [19–263]) | 27 (25–30 [19–263])                                      | 31 (27.1–36 [24–50])                                      | 0.12    |
| Missing | 1           | 1                                                        |                                                          |         |
| Plasma creatinine; μmol.l⁻¹ | 70 (54–107 [27–396]) | 67 (52–104 [27–396])                                      | 157 (112–212 [44–244])                                     | 0.014   |
| N-terminal pro B-type natriuretic peptide; ng.l⁻¹ | 458 (199–1690 [36–61,280]) | 429 (197–1369 [36–31,136])                                | 4806 (2571.5–17,121 [131–61,280])                         | 0.006   |
| Missing | 12          | 1                                                        |                                                          |         |
| N-terminal pro B-type natriuretic peptide > 300 ng.l⁻¹ | 63 (63%) | 57 (61%)                                                 | 6 (86%)                                                  | 0.255   |
| Missing | 12          | 12                                                       |                                                          |         |
| High-sensitivity troponin I; ng.l⁻¹ | 12 (5–42 [0–3585]) | 11 (4–37 [0–3585])                                       | 56 (38–102 [6–278])                                        | 0.082   |
| Missing | 48          | 46                                                       |                                                          |         |
| High-sensitivity troponin I; ng.l⁻¹ | 17 (10–29 [0–473]) | 16 (10–26 [0–473])                                       | 39 [34–44 [29–49])                                         | 0.094   |
| Missing | 66          | 61                                                       |                                                          |         |
| Raised plasma troponin | 51 (46%) | 45 (44%)                                                 | 6 (86%)                                                  | 0.048   |
| Missing | 2           | 2                                                        |                                                          |         |

(continued)
Table 3 (continued)

|                                | All n = 112 | No or less than severe right ventricular dysfunction n = 105 | Severe right ventricular dilation and septal flattening n = 7 | p value |
|--------------------------------|-------------|-------------------------------------------------------------|-------------------------------------------------------------|---------|
| Heart rate; beats.min⁻¹        | 79 (19.9)   | 77.7 (19.5)                                                 | 99.1 (17.3)                                                 | 0.016   |
| Rhythm                         |             |                                                             |                                                             |         |
| Sinus                          | 107 (96%)   | 100 (95%)                                                   | 7 (100%)                                                   | > 0.99  |
| Atrial tachycardia             | 5 (5%)      | 5 (5%)                                                      | 0                                                          |         |
| Mean arterial pressure; mmHg   | 81 (13.4)   | 81 (13.5)                                                   | 74 (9.6)                                                   | 0.1     |
| Missing                        | 3           | 3                                                           | 0                                                          |         |
| Central venous pressure; cmH₂O| 7 (4–12 [0–25]) | 7 (4–12 [0–20.4])                              | 14 (10–17 [2–25])                               | 0.187   |
| Missing                        | 38          | 35                                                          | 3                                                          |         |
| Vasopressors                   | 40 (36%)    | 36 (34%)                                                    | 4 (57%)                                                    | 0.246   |
| Inotropes                      | 1 (1%)      | 1 (1%)                                                      | 0                                                          | > 0.99  |
| Anticoagulation                |             |                                                             |                                                             |         |
| Prophylactic                   | 93 (83%)    | 90 (86%)                                                    | 3 (43%)                                                    | 0.018   |
| Therapeutic                    | 17 (15%)    | 13 (12%)                                                    | 4 (57%)                                                    |         |
| None                           | 2 (2%)      | 0                                                           | 0                                                          |         |
| Neuromuscular blockade         | 52 (46%)    | 49 (47%)                                                    | 3 (43%)                                                    | > 0.99  |
| F₁O₂                            | 0.6 (0.4–0.7 [0.3–1.0]) | 0.6 (0.4–0.7 [0.3–1.0])                              | 0.6 (0.5–0.7 [0.4–0.8])                                 | 0.659   |
| Requirement for prone ventilation in previous 24 h | 44 (39%) | 40 (38%) | 4 (57%) | 0.468 |
| Plateau airway pressure; cmH₂O| 24 (22–27 [12–41]) | 24 (22–27 [12–41])                              | 27 (27–29 [26–31])                               | 0.048   |
| Missing                        | 54          | 52                                                          | 2                                                          |         |
| Peak airway pressure; cmH₂O    | 25 (20–30 [2–41]) | 25 (20–29 [2–41])                              | 29 (27–31 [11–31])                               | 0.171   |
| Missing                        | 54          | 52                                                          | 2                                                          |         |
| Tidal volume based on predicted body weight; ml.kg⁻¹ | 7.2 (2.1) | 7.2 (2.0) | 7.1 (3.3) | 0.978 |
| Missing                        | 4           | 2                                                           | 0                                                          |         |
| PaO₂/F₁O₂                       | 17 (13.6–21.3 [5.6–33.3]) | 17.5 (13.7–21.5 [5.6–33.3]) | 15.6 (12.5–17.5 [10.1–24.4]) | 0.361 |
| PEEP; cmH₂O                    | 9.8 (3.6)   | 9.9 (3.6)                                                   | 8.7 (3.0)                                                  | 0.351   |
| Missing                        | 1           | 1                                                           | 0                                                          |         |
| Respiratory rate; breaths.min⁻¹| 24.3 (5.3) | 24.2 (5.2) | 25.3 (6.3) | 0.676 |
| Driving pressure; cmH₂O        | 14.7 (7.1)  | 14.2 (7.1)                                                  | 19.4 (5.1)                                                 | 0.086   |
| Missing                        | 54          | 52                                                          | 2                                                          |         |
| Dynamic compliance; ml.cmH₂O⁻¹| 30 (20–40 [8–180]) | 32 (21–41 [8–180])                              | 19 (17–20 [13–32])                               | 0.031   |
| Missing                        | 54          | 52                                                          | 2                                                          |         |
| Murray lung injury score       | 3 [2–3 [1–4]] | 3 [2–3 [1–4]] | 2.9 [3–3 [2–4]] | 0.491 |
| Missing                        | 12          | 11                                                          | 1                                                          |         |

RRT, renal replacement therapy.
with evidence of both pressure and volume overload [20]. The observed prevalence of right ventricular dysfunction seen in the current study at 6% was lower than hypothesised. In the early phases of the pandemic, anecdotal clinical reports and early peer-reviewed literature suggested right ventricular dysfunction was very common [21]. These early studies had mechanical ventilation rates of only 10–30% and it was hypothesised the prevalence of right ventricular dysfunction would be higher in a cohort requiring tracheal intubation and mechanical ventilation. Previous reports of right ventricular dysfunction in ARDS described a prevalence of up to 50% [10,22].

The lower-than-expected prevalence of right ventricular dysfunction may have been observed for several reasons. First, these early, observational and retrospective reports are likely to have been influenced by both ascertainment and selection bias, where assessments were only performed for clinical purposes, in all likelihood in patients who were haemodynamically unstable or deteriorating, meaning prevalence was over-reported [21]. We recruited 24% of all patients admitted to participating ICUs during the study period; the prospective and systematic approach to patient recruitment provides confidence that the prevalence presented here is accurate. When compared with contemporaneous national reporting by both the Intensive Care National Audit and Research Centre and the Scottish Intensive Care Society Audit Group, patients recruited in our study are representative in terms of severity of illness and mortality [23,24]. Second, there were significant differences in baseline characteristics, clinical care and outcomes between the time of these early reports and the UK second wave when our cohort was recruited. Attitudes to non-invasive respiratory support, ventilation practice, fluid management and anticoagulation all evolved and successful drug therapies were discovered and implemented. For example, 66% of participants were treated with intravenous steroids before tracheal intubation [25,26]. Third, the definition of right ventricular dysfunction used in this study, necessitating the presence of both severe dilation and septal flattening, is a more stringent definition than that used in other reports. The alternative outcome we employed was found in 30% of patients, while subjective right ventricular dysfunction was diagnosed in 14%. This is consistent with previous studies in COVID-19, where right ventricular dilation was reported to be present in 31–52% of cases [2,4,5,11].

Our findings are in keeping with previous reports in ARDS. In a study of 752 patients by Mekontso Dessap et al.
acute cor pulmonale was present in 22% (95%CI 19–25%) and severe acute cor pulmonale (the same definition as used in our study) was present in 7% (95%CI 5–9%). As in our study, hospital mortality was only higher in patients with severe acute cor pulmonale when compared with all other patients (57% vs. 42%; p = 0.03), suggesting this definition of right ventricular dysfunction identifies a population of patients where the diagnosis yields significant clinical sequelae. High driving pressure, low PaO$_2$/FiO$_2$ ratio and high PaCO$_2$ have been associated with right ventricular dysfunction in patients with ARDS [10]. Although we were not able reproduce these findings, our study demonstrates that plateau airway pressure was higher and compliance lower in those with right ventricular dysfunction, suggesting interplay between ARDS and the conduct of mechanical ventilation in the aetiology of right ventricular dysfunction in this population.

The observed association between confirmed or suspected thromboembolic disease and right ventricular dysfunction is not unexpected and demonstrates the role of macrothrombi in right ventricular dysfunction. It has been consistently demonstrated that patients with COVID-19 in ICU have a high frequency of thrombotic complications with an incidence of 13% [27]. Right ventricular dysfunction is common in patients with thromboembolic disease and is a major determinant of short-term survival [28]. Cardiomyocyte injury, quantified by elevated troponin levels, and haemodynamic cardiac stress, as quantified by

Figure 3  N-terminal pro B-type natriuretic peptide levels in of patients with COVID-19 whose lungs were mechanically ventilated with and without right ventricular dysfunction.
increased natriuretic peptide concentrations, have been described both in COVID-19 and ARDS [29,30]. The association of elevated plasma NT-proBNP and abnormal troponin levels with right ventricular dysfunction in this cohort suggests a potential role of direct myocardial injury in the aetiology of myocardial dysfunction in patients with COVID-19.

Our study used a single time-point of echocardiographic assessment and it is unknown whether patients classified as not having right ventricular dysfunction may have had abnormal echocardiography if imaging had occurred at a different time-point during their ICU admission. Although we have precisely estimated the prevalence of right ventricular dysfunction in patients with COVID-19 whose lungs are mechanically ventilated, the low number of patients fulfilling the primary outcome prevents detailed multivariate assessment of the factors associated with right ventricular dysfunction. In addition, the associations explored between right ventricular dysfunction and aetiological factors are at risk of type 1 and 2 errors, meaning they can only be considered exploratory in nature.

In conclusion, we have demonstrated that the prevalence of right ventricular dysfunction is lower than predicted in patients with COVID-19 whose lungs are mechanically ventilated but that there is an association between this and mortality. We observed an association between right ventricular dysfunction and each of the aetiological domains of: ARDS; mechanical ventilation; thromboembolic disease; and myocardial injury. This serves to highlight the need for increased clinician awareness of right ventricular dysfunction and aids the design of therapeutic studies seeking to improve outcomes in this critically ill patient group.

Acknowledgements

The COVID-RV study was registered with ClinicalTrials.gov (NCT04764032). This work was supported by Medical Research Scotland (CVG-1730-2020). The funding body had no input in the design of the study and collection, analysis and interpretation of data or the writing the manuscript. BS is employed by the University of Glasgow which holds consultancy and research agreements for his work with Abbott Vascular, AstraZeneca, Boehringer Ingelheim, Causeway Therapeutics, Coroventis, Genentech, GSK, HeartFlow, Menarini, Neovasc, Siemens Healthcare and Valo Health. No other competing interests declared.

References

1. Michard F, Gonzalez F. Coronavirus disease 2019: there is a heart between the lungs. Critical Care Medicine 2021; 49: 1832–5.
2. Szekely Y, Lichter Y, Taieb P, et al. Spectrum of cardiac manifestations in COVID-19. Circulation 2020; 142: 342–53.
3. Michard F, Vieillard-Baron A. Critically ill patients with COVID-19: are they hemodynamically unstable and do we know why? Intensive Care Medicine 2021; 47: 254–5.
4. Argulian E, Sud K, Vogel B, et al. Right ventricular dilation in hospitalized patients with COVID-19 infection. Journals of the American College of Cardiology: Cardiovascular Imaging 2020; 13: 2459–61.
5. Li Y, Li H, Zhu S, et al. Prognostic value of right ventricular longitudinal strain in patients with COVID-19. Journals of the American College of Cardiology: Cardiovascular Imaging 2020; 13: 2287–99.
6. D’Alto M, Marra AM, Severino S, et al. Right ventricular-arterial uncoupling independently predicts survival in COVID-19 ARDS. Critical Care 2020; 24: 670.
7. Doyen D, Dupland P, Morand L, et al. Characteristics of cardiac injury in critically ill patients with coronavirus disease 2019. Chest 2021; 159: 1974–85.
8. Park JF, Banerjee S, Umar S. In the eye of the storm: the right ventricle in COVID-19. Pulmonary Circulation 2020; 10: 2045894020936660.
9. Boissier F, Katshahian S, Raazi K, et al. Prevalence and prognosis of cor pulmonale during protective ventilation for acute respiratory distress syndrome. Intensive Care Medicine 2013; 39: 1725–33.
10. Mekontso Dessap A, Boissier F, Charron C, et al. Acute cor pulmonale during protective ventilation for acute respiratory distress syndrome: prevalence, predictors, and clinical impact. Intensive Care Medicine 2016; 42: 862–70.
11. Chotalia M, Ali M, Alderman JE, et al. Right ventricular dysfunction and its association with mortality in coronavirus disease 2019 acute respiratory distress syndrome. Critical Care Medicine 2021; 49: 1757–68.
12. Willder JM, McCall P, Messow C-M, Gillies M, Berry C, Shelly B. Study protocol for COVID-RV: a multicentre prospective observational cohort study of right ventricular dysfunction in ventilated patients with COVID-19. British Medical Journal: Open 2021; 11: e042098.
13. Intensive Care Society. Focused ultrasound for intensive care 2021. https://www.ics.ac.uk/ICS/FUSIC/FUSIC_Accreditation/ICS/FUSIC/FUSIC_Accreditation.aspx?hkey=03ef026c-cd0c-4bba-9555-8c85bb220b01 (accessed 17/02/2021).
14. Heineze G, Schenper M. A solution to the problem of separation in logistic regression. Statistics in Medicine 2002; 21: 2409–19.
15. Murray JF, Matthay MA, Luce JM, Flick MR. An expanded definition of the adult respiratory distress syndrome. American Review of Respiratory Disease 1988; 138: 720–3.
16. Lainm T, Douglas IS, Archer SL, et al. Assessment of right ventricular function in the research setting: knowledge gaps and pathways forward. An official American Thoracic Society research statement. American Journal of Respiratory and Critical Care Medicine 2018; 198: e15–43.
17. Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography

©2022 The Authors. Anaesthesia published by John Wiley & Sons Ltd on behalf of Association of Anaesthetists.
Appendix 1 COVID-RV co-investigators.

A Reece, C Kitchen, M Gillies, V Dabek, V Irvine, COVID-RV trial management group, Glasgow, UK.

J MacBrayne, K Sim, T Scott, E Trumper, F Savage, A Allan, J Falconer, A Coutts, Aberdeen Royal Infirmary, Aberdeen, UK.

A McDonald, J Rutherford, D Christie, C Jardine, Dumfries & Galloway Royal Infirmary, Dumfries, UK.

M Hughes, S Cathcart, Glasgow Royal Infirmary, Glasgow, UK.

M Sim, B Docking, M Thornton, Queen Elizabeth University Hospital, Glasgow, UK.

B Greatorex, J Rae, C Barr, C Bradley, F Barrett, R Campbell, N Clarke, M Mascarenhas, J Matheson, D McDonald, M O’Hara, L O’keeffe Raigmore Hospital, Inverness, UK.

R Price, M McHendry, Royal Alexandra Hospital, Paisley, UK.

D McLaughlan, C Herman, H Elliot, S Meehan, University Hospital Ayr, Ayr, UK.

D Finn, G Brannan, S Wood, T Watson, K Ross, University Hospital Crosshouse, Kilmarnock, UK.

N Tatarkowska, R Boyle, E Lee, University Hospital Hairmyres, East Kilbride, UK.

A Morrison, P. Lucie, C Lochrin, S Clements, D Vigni, University Hospital Wishaw, Wishaw, UK.

Supporting Information

Additional supporting information may be found online via the journal website.

Table S1. Differences in mortality rates.

Table S2. Patient characteristics at ICU admission for the post-hoc outcome.

Table S3. Measured echocardiographic variables for the post-hoc outcome.

Table S4. Patient characteristics on the day of echocardiography for the post-hoc outcome.

Table S5. Clinical outcomes of included patients at 30 days following echocardiography for the post-hoc outcome.

Table S6. Firth’s bias reduced logistic regression for 30-day mortality for the post-hoc outcome.